New York, NY (PRWEB) July 18, 2014
Concerns surrounding certain testosterone treatments (http://www.injurybeacon.com/testosterone-androgel/) continued to reach new heights this month with a new study that found a significant increase in the number of Canadian men taking the medications over 15 years, Bernstein Liebhard LLP reports.
The study was published July 16th in an online version of the journal PLOS ONE, and revealed a 310 percent increase in Ontario men using testosterone-raising treatments between 1997 and 2012. According to a Huffington Post report that relayed its results, 28,477 men aged 66 and older were included in the research, which also found that only 6 percent of individuals taking the drugs were diagnosed with hypogonadism, a condition associated with abnormally-low levels of the hormone.*A number of testosterone lawsuits filed in the U.S. allege strokes, heart attacks, blood clots and other cardiovascular problems caused by hormone-raising treatments, court documents indicate.
“As our Firm continues to hear from men who allegedly sustained heart attacks, strokes deep vein thrombosis and other serious heart problems after taking AndroGel, Testim and several other medications, we find the results of this study deeply troubling,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential testosterone lawsuit evaluations to men who were allegedly harmed as a result of these hormone-raising therapies.
According to court documents updated on July 15th, a least 156 testosterone lawsuits are now pending in a multidistrict litigation (MDL) currently underway in the U.S. District Court, Northern District of Illinois. Cases filed in this proceeding allege that the makers of AndroGel and other medications failed to adequately warn men and about cardiovascular side effects that may stem from use of their products.
The litigation surrounding low testosterone therapies has continued to grow since January, when the U.S. Food and Drug Administration (FDA) issued a public health alert that vowed to investigate the safety of “Low T” testosterone medications. The warning was issued on January 31, 2014, after two studies revealed an increased risk for heart attacks, strokes and death in younger men with pre-existing heart disease and all older men.
Men who may have been harmed due to their use of drugs like Androgel may be entitled to file their own testosterone treatment lawsuit. To learn more, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
Huffington Post, July 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/testosterone-lawsuit/androgel-lawsuit/prweb12029668.htm.
Copyright©2014 Vocus, Inc.
All rights reserved